Targeting a lipid receptor to improve stroke treatment
Official title: Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
Funded at Oasis Pharmaceuticals · NIH-11137505 · Data updated 2026-11-12
This study is looking at a special receptor called GPR31 to see if blocking it can help prevent blood clots and protect the brain during a stroke, which could lead to better treatments for stroke patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oasis Pharmaceuticals NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $50,000 |
| NIH project number | 3R42HL160429-03S1 |
| Project ID | NIH-11137505 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are at risk of or have experienced an acute stroke.
✕Less likely to help
Patients who are under 21 years old or those with conditions unrelated to stroke may not benefit from this research.
What this research studies
This research investigates the lipid receptor GPR31 as a potential target for developing new therapies to prevent blood clots and protect the brain after a stroke. The approach focuses on understanding how bioactive fatty acids influence inflammation and metabolism, particularly in the context of stroke. By blocking GPR31, the researchers aim to create a safer and more effective treatment that not only prevents clot formation but also protects brain cells from damage during a stroke. This could lead to improved outcomes for stroke patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce the risk of stroke-related disabilities and improve recovery outcomes for patients.
How similar studies have gone: Other research has shown promise in targeting lipid receptors for therapeutic purposes, indicating potential success for this novel approach.
Where this research is happening
-
Oasis Pharmaceuticals
Lexington, United States Active
Researchers
- Principal investigator: Kuliopulos, Athan — Oasis Pharmaceuticals
- Study coordinator: Kuliopulos, Athan
Related research
Other NIH-funded projects on the same topics.
-
Stroke prevention with hydroxyurea for children with sickle cell anemia in Nigeria
A multinational, patient-facing study tests whether hydroxyurea can safely prevent first strokes in Nigerian children with sickle cell anemia.
-
Music-powered tools to boost blood pressure and stroke prevention for Nigerian youth and their older caregivers
This project uses popular music to help Nigerian youths and their older family members start and stick to blood pressure and stroke prevention habits.
-
Determinants of Post-Stroke Cognitive Outcomes and Vascular Effects on Recovery
A large, multi-site effort aims to understand why some stroke survivors develop long-term cognitive problems and dementia, and how vascular health and pre-existing brain changes influence recovery.
-
LRP1 controls NSC movement and stroke recovery
This NIH grant studies how a brain receptor called LRP1 helps neural stem cells move to stroke injuries and support recovery in adults.
-
BBB Dysfunction after Stroke and Risk for Dementia
A study at Stanford will look at whether inflammation after a stroke leads to leaky blood vessels and later dementia, by following stroke survivors and comparing them with people without stroke.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.